A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness (Q83098432)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Tom C Fardon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Patricia Burns

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Martyn L Barnes

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Brian J Lipworth

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

Annals of Allergy, Asthma & Immunology

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

422-430

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Inflammation of small airways in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

The structure of large and small airways in nonfatal and fatal asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Variability of airway structure and inflammation in normal subjects and in cases of nonfatal and fatal asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

The comparative safety/efficacy ratio of HFA-BDP.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Budesonide treatment of moderate and severe asthma in children: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Caffeine decreases exhaled nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs☆☆☆★★★

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Asymptomatic airway hyperresponsiveness: relationships with airway inflammation and remodelling

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Exhaled nitric oxide in asthma: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Airway inflammation is present during clinical remission of atopic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Adrenal suppression with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960909-X

7 January 2021

10.1016/S1081-1206(10)60909-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16597076%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference